News provided by
Financial Press Media Group Inc.
October 28, 2016
Share this article
SANTA MONICA, CA, Oct. 28, 2016 /PRNewswire/ - Financial Press covers BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP™ System, a novel cardiac electrophysiology (EP) information system.
In a major milestone, BioSig recently announced that the prestigious Journal of the American College of Cardiology (JACC) has published an online article entitled "Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals" by Ammar M. Killu, MBBS, Niyada Naksuk, MD, Kalpathi L. Venkatachalam, MD, and Samuel J. Asirvatham, MD from the renowned Mayo Clinic.
In a recent press release, Greg Cash, President and Chief Executive of BioSig Technologies, stated: "Publication of these exciting findings in a peer reviewed journal such as JACC: Clinical Electrophysiology indicates the importance of these previously unavailable capabilities and their potential to advance the diagnosis and treatment of complex cardiac arrhythmias."
Ventricular fibrillation (VF), ventricular tachycardia (VT) and atrial fibrillation (AF) are a few conditions referred to as an arrhythmia. AF is the most widespread, affecting approximately 33 million people worldwide, and 6.1 million in the U.S. according to the Centers for Disease Control and Prevention (CDC).
There is a well-documented correlation between AF and stroke and other associated risks, such as heart failure. Research shows that catheter ablation therapy for treatment of arrhythmia patients is still not a perfect science. New electrophysiology (EP) device technologies, like BioSig's PURE EP System, are needed to improve this procedure's success rates. Many of today's EP systems have limited dynamic range, which translates into problems when amplifying small cardiac signals in order to see them, ultimately distorting and saturating large signals. Electrical noise is also an issue, which makes it difficult for clinicians to differentiate real physiologic signals from noise. It is with the mission of solving these and other issues that BioSig developed its PURE EP System, a technology that is poised to capture a significant portion of the rapidly growing EP market.
BioSig's PURE EP System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
The JACCCEP publication highlighted PURE EP's ability to detect and visualize high-frequency signals in the presence of larger waveforms as well as its capability to display the same channel with different processing options to highlight specific features while still displaying the original electrogram signal.
Legal Disclaimer: Financial Press Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Financial Press Media Group, Inc. may have received compensation from the companies mentioned in this release.
SOURCE Financial Press Media Group Inc.